CorInnova is a Houston-based company that is developing a minimally invasive, non-blood contacting cardiac assist device for the treatment of acute heart failure. Their innovative device, which is collapsible and conforms to the heart's surface, gently compresses the heart to increase cardiac output using an external pneumatic driver that operates in synchrony with the heartbeat. By eliminating the need for blood contact, the device reduces the risk of thrombosis, stroke, and other complications associated with existing cardiac assist devices. With a lead investment from Wellcome Trust, CorInnova aims to address the large and fast-growing short-term cardiac assist market, expanding it to an $8 billion addressable market by providing a solution for the 50% of patients who cannot use or are unsuitable for current cardiac assist devices. Their technology has received recognition and awards, and their preclinical results have been published in prestigious journals, positioning CorInnova as a promising player in the field of heart failure treatment.Generated from the website

Katherine P. Lemon, MD, PHD

Brent A. Mothner, MD

Baylor College Medicine Inf Dis

Sherman Lori-Plastic Surgery/Cranial Associates